Some biotech investors had probably never heard of exosomes until Codiak’s chief executive, Doug Williams, made his pitch at the JP Morgan conference two weeks ago. But the area has been gaining traction, and Jazz’s $56m up-front...
Read More »Roche to apply PureTech exosomes platform for the oral administration of antisense oligonucleotides
PureTech Health, a clinical-stage biopharmaceutical company developing novel medicines focused on the Brain-Immune-Gut (BIG) Axis, today announced that it has entered into a multiyear collaboration with...
Read More »